The effect of the proportion of low-titer O whole blood for resuscitation in pediatric trauma patients on 6-, 12- and 24-hour survival

J Trauma Acute Care Surg. 2025 Apr 1;98(4):587-592. doi: 10.1097/TA.0000000000004564. Epub 2025 Feb 3.

Abstract

Introduction: Hemorrhage is a leading cause of death in pediatric patients. Accumulating data suggest that low-titer group O whole blood (LTOWB) improves clinical outcomes in the pediatric population. We examined what ratio of LTOWB to total blood product conferred a survival benefit in transfused pediatric trauma patients.

Methods: We retrospectively examined a cohort of injured subjects younger than 18 years from the Trauma Quality Improvement Program database who received any quantity of LTOWB and no documented prehospital cardiac arrest. We created a variable representing the volume of transfused LTOWB divided by the total volume of all transfused blood products administered within the first 4 hours of admission, that is, the proportion of LTOWB transfused. We analyzed increasing proportions of transfused LTOWB to determine whether there was an inflection point conferring increased survival.

Results: From 2020 to 2022, 1,122 subjects were included in the analysis. The median (interquartile range) age was 16 (14-17) years. Firearms were the most common mechanism at 47% followed by collisions at 44%. The median composite injury severity score was 25 (16-34). Survival was 91% at 6 hours, 89% at 12 hours, and 88% at 24 hours. We noted an inflection point with improved survival at an LTOWB proportion of ≥30% of total volume of blood products received. The odds of survival at 6, 12, and 24 hours for those receiving ≥30% LTOWB was 1.85 (1.02-3.38), 2.09 (1.20-3.36), and 1.80 (1.06-3.08), and 3.55 (1.66-7.58), 3.71 (1.89-7.27), and 2.69 (1.44-5.02) when excluding those who died within 1 hour, respectively.

Conclusion: Among LTOWB recipients, we found that a strategy of using LTOWB comprising at least 30% of the total transfusion volume within the first 4 hours was associated with improved survival at 6, 12, and 24 hours.

Level of evidence: Therapeutic/Care Management; Level III.

Trial registration: ClinicalTrials.gov NCT06070350.

MeSH terms

  • ABO Blood-Group System*
  • Adolescent
  • Blood Transfusion* / methods
  • Blood Transfusion* / statistics & numerical data
  • Child
  • Female
  • Hemorrhage* / etiology
  • Hemorrhage* / mortality
  • Hemorrhage* / therapy
  • Humans
  • Injury Severity Score
  • Male
  • Resuscitation* / methods
  • Resuscitation* / mortality
  • Retrospective Studies
  • Time Factors
  • Wounds and Injuries* / blood
  • Wounds and Injuries* / complications
  • Wounds and Injuries* / mortality
  • Wounds and Injuries* / therapy

Substances

  • ABO Blood-Group System

Associated data

  • ClinicalTrials.gov/NCT06070350